Dutch firm Argenx Euronext: ARGX) and China’s Zai Lab (HKEX: 9688) have received an approval from the National Medical ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Zai Lab (NASDAQ:ZLAB) is scheduled to announce Q3 earnings results on Tuesday, November 12th, before market open. The consensus EPS Estimate is -$0.78 and the consensus Revenue Estimate is $102.24M ...

(ARGX) and Zai Lab Limited (ZLAB) announced that China’s National Medical Products Administration, NMPA, approved the supplemental ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

Zai Lab (NASDAQ:ZLAB) stock rose 5% in early trading Monday after the company announced that Vyvgart Hytrulo’s regulatory ...

Zai Lab Limited (NASDAQ: ZLAB) and argenx (NASDAQ: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for ...

Peraton understands that honoring those who have served our country in the military is our patriotic duty. The company proudly has more than 4,000 veterans, active duty, and reservists ? nearly a ...

IBN ? Annovis Bio, Inc. ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...